✅ Michelle Petri in the VERY FULL #ACR23 early session about #lupus: BEFORE stepping-up with biologics, ask the key questions: -Are you using proton-pump inhibitors (Drug-induced SCLE) -Can I see your sunscreen? -Can I see your hat? -Are you smoking? -Any HCQ blood levels? https://t.co/s73FqyjLOn

Conundrum of #Clinically #Quiescent #Serologically #Active #SLE-half flare within 5 yrs; can have organ damage. Large cohort-China 20% met def’n- diff trajectories 37% flare 1/6 got damage in f/u Some tapered Rx How to identify safe to d/c Rx? 2555 #ACR23 @ACRheum @RheumNow https://t.co/f49BQspQsz

#Lupus #nephritis - #inflammatory #fibrosis predicts #renal damage on #kidney #bx @ACRheum @RheumNow #ACR23 #2552 - similar in CRF from #Diabetes etc Biomarker is i-IFTA - same as other CRF diseases https://t.co/2LNn5Wn7rJ

What % of pts in #RCTs in #SLE go in to #LLDAS - Pooling 5 RCTs - starting on #belimumab vs #placebo? More w #bDMARD @RheumNow @ACRheum #ACR23 abst#2551. True w DORIS - #lupus #rem but overall lower rates in each group https://t.co/VPZrYCVjof

After attaining #remission or #LLDAS after a flare - HALF flare over f/u esp if tapering pred to <7.5 or 5 mg. #HCQ was protective. 65% got LLDAs and 45% rem in 1/2 yr - longer time to get #remission #2553 #ACR23 @RheumNow @ACRheum #ACRbest Asian cohort of #SLE largest@in world https://t.co/yBBqYJZVOe

Wouldn’t it be great to assess immune changes in #SLE before #clinical #lupus #flare? Without over treatment too! YOU CAN Lupus flare risk index calculated prior to disease activity change or stable pt. Results combined for score 11 mediators #ACR23 @RheumNow @ACRheum abst#2554 https://t.co/gUimJLrJ33

The Lupus APOL1 Story Dr. Kathryn Dao talks with Dr. Ashira Blazer, Rheumatology Research Foundation Dubois Memorial Lecturer on APOL1 High Risk Genotype in SLE: A Genes in Context Story, at the 2023 ACR Convergence meeting in San Diego, CA. #ACR23 https://t.co/VXxJxk0kbS https://t.co/1n1COXcYA4

• The Lupus APOL1 Story | RheumNow

Who uses #cannabis in #rheumatic #diseases? Those who smoke, have higher pain, more anxiety, poor sleep are more likely to have used cannabis for their rheumatic disease. Half of the >2900 respondents have tried #cannabis. Use of #biologics reduced use. #980 @RheumNow @ACRheum https://t.co/DQDRQN40zR

#ACR23 Abstr# 2488 Phase 2 RCT #SLE showed more patients on ABBV-599 HD (elsubrutinib (BTK-i) + UPA (JAK-i)) and UPA monotherapy met primary & secondary endpoints vs PBO at WK48W. No major malignancy/VTE concerns. No added superiority by adding BTK-i vs UPA alone @RheumNow https://t.co/MUN2o75gEE

During "Rashes in Rheumatology talk at #ACR23, Dr. Katherine Shaw does not routinely use HCQ for DM skin manifestations. ⭐️Only ~10% of DM patients respond to monotherapy with HCQ but potential increased risk of hypersensitivity, especially in MDA5-DM ➡️Suspect that slight HCQ… https://t.co/aRmFmzuAum

HCQ and risk of retinopathy 👁️ DoD database HCQ 44000+ females & 10000+ males Risk retinopathy HR 1.5 Variations according to diagnosis SLE higher risk vs. RA, more so in males HR 2, females HR 1.7 No adjustment on HCQ dose @RheumNow #ACR23 ABST2452 https://t.co/TtTu6ixb45

#ACR23 Abstr# 2489 I can’t wait for Phase 3 RCT results as I have many #SLE patients with refractory cutaneous lupus. Post-hoc analyses of Phase 2 RCT of Deucravacitinib showed its efficacy (CLASI-50) over PBO across all CLE subtypes @RheumNow https://t.co/G7edkAU18J